Dime

Koneksa Appoints Dr. Jessie Bakker as Vice President of Clinical Development

Retrieved on: 
Monday, March 4, 2024

Koneksa , the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President (VP) of Clinical Development.

Key Points: 
  • Koneksa , the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President (VP) of Clinical Development.
  • She brings a wealth of experience that will play a pivotal role in shaping Koneksa’s clinical program strategy from development through life-cycle management.
  • Dr. Bakker has extensive experience in the development, validation, and deployment of digital tools in clinical trials within academia as well as with several device manufacturers.
  • Dr. Bakker also has technology industry experience and held positions at Signifier Medical Technologies as the Executive Vice President of Medical Affairs, and at Philips Sleep and Respiratory Care as the Associate Director of Clinical Affairs.

Foundational V3 Framework Extended to Incorporate Usability Validation of Sensor-Based Digital Health Technologies

Retrieved on: 
Tuesday, February 27, 2024

BOSTON, Feb. 27, 2024 /PRNewswire/ -- To support the rapid evolution of digital clinical measures, today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released an extension of its foundational Verification, Analytical Validation, and Clinical Validation (V3). The V3+ extension adds a fourth component of "Usability Validation," incorporating the evaluation of user experience at scale. Additional resources, a supporting manuscript, and new educational material are now available to make it easy for developers to implement it as they build sensor-based digital health technologies (sDHTs).

Key Points: 
  • BOSTON, Feb. 27, 2024 /PRNewswire/ -- To support the rapid evolution of digital clinical measures, today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released an extension of its foundational Verification, Analytical Validation, and Clinical Validation (V3).
  • The V3+ extension adds a fourth component of "Usability Validation," incorporating the evaluation of user experience at scale.
  • The three components of the original V3 framework remain unchanged; the V3+ framework is now extended to evaluate the ease of use, efficiency, and user satisfaction of sDHTs.
  • "I was proud to join DATAcc in the development of V3+ to include usability as a requirement in this framework.

CancerX Announces Inaugural Start-Up Accelerator Cohort

Retrieved on: 
Monday, February 26, 2024

BOSTON, Feb. 26, 2024 /PRNewswire/ -- Today on the Central Stage at ViVE 2024, CancerX announced the 16 start-up members of its inaugural Accelerator cohort, launched in partnership with MassChallenge: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, LindAI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, and Xanthos. 

Key Points: 
  • The collaborative environment fostered by this unique Accelerator will promote cross-pollination of ideas within cohort, spurring further innovation."
  • "We are proud to be the first to formalize the support for early-stage digital innovation in oncology through the CancerX Accelerator.
  • CancerX will build on the success of the inaugural round and plans to open Accelerator applications for a second cohort in the fall of this year.
  • For more information about the CancerX Accelerator and updates on future cohorts, please visit the website or sign up to receive CancerX newsletters.

Gesund.ai Partners with VALID AI and U.S. AI Safety Institute Consortium to Promote Development and Deployment of Trustworthy Medical Artificial Intelligence

Retrieved on: 
Monday, February 26, 2024

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Gesund.ai, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined both VALID AI and the U.S. Artificial Intelligence Safety Institute Consortium (AISIC) as a member. The partnerships allow Gesund.ai to power the validation infrastructure for VALID AI member health systems, while working closely alongside government bodies like the Department of Commerce to help establish best practices for using medical AI.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Gesund.ai , the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined both VALID AI and the U.S.
  • Artificial Intelligence Safety Institute Consortium (AISIC) as a member.
  • VALID AI stands for Vision, Alignment, Learning, Implementation, and Dissemination of Validated Generative AI in Healthcare.
  • The AISIC brings together a consortium of AI creators, academics, government and industry researchers, and civil society organizations in support of the development and deployment of safe and trustworthy AI.

Innsena Announces Impact Partnership with CancerX

Retrieved on: 
Tuesday, February 13, 2024

Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .

Key Points: 
  • Innsena , a health tech consultancy focused on improving care outcomes for underserved communities, today announced its partnership with CancerX , a public-private partnership announced by The White House as a national accelerator to boost digital innovation in the fight against cancer as part of the reignited Cancer Moonshot .
  • Innsena joins the initiative as its first Impact Supporter.
  • As a CancerX Impact Partner, Innsena will work collaboratively with the public-private partnership to advise on health disparities, the needs of the underserved, access to care and rural and tribal community, and other needs as its programs evolve.
  • “We’re grateful Innsena has chosen to join the CancerX community,” says Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe) , co-host of CancerX.

DATAcc by DiMe Launches Digital Strategy for Standardized Measurement of Physical Activity

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures for physical activity, providing a roadmap for leveraging digital tools to measure the '6th vital sign.' Researchers and healthcare professionals can now better assess and address the impact of exercise on an individual's well-being. The measures were developed in partnership with industry leaders following a cross-disciplinary, evidence-based research project. New resources – including ontologies, a decision tool, and illustrative scenarios – provide specific support to clinical researchers, healthcare providers and decision-makers, and digital health technology developers to effectively implement these new core measures.

Key Points: 
  • Core measures and other resources are now available to support an industry standard for digitally measured physical activity, increasingly recognized as the '6th vital sign'
    BOSTON, Feb. 13, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures for physical activity , providing a roadmap for leveraging digital tools to measure the '6th vital sign.'
  • The importance of physical activity to health has long been recognized, and technology exists today to seamlessly measure it in the broad population.
  • "This new core set of digital measures for physical activity will advance the industry by reducing duplicative efforts and speeding the path to discoveries that will benefit the patients we aim to serve," said Jennifer Goldsack, CEO of DiMe.
  • Building off this momentum and extending its portfolio of digital measures work , DATAcc is now convening a project team to build the business case for digital endpoints.

Digital Medicine Society Convenes Industry Leaders to Streamline Path to Commercial Success for Digital Health Product Developers

Retrieved on: 
Tuesday, January 23, 2024

BOSTON, Jan. 23, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) announced it's partnering with Peterson Health Technology Institute (PHTI), ZS Associates, and other leading industry organizations to define how Integrated Evidence Plans (IEP) can be developed, optimized, and used to support the regulatory and commercial success of digital health products (DHPs) on an accelerated timeline. The goal is to streamline the pathways to successful commercialization of high-value, evidence-based DHPs, addressing the top priority reported by industry leaders in DiMe's recent Digital Health Industry Regulatory Needs Assessment: to align best practices between regulatory requirements and decision-making with downstream payers and purchasers.

Key Points: 
  • In today's rapidly evolving and maturing business landscape, addressing the challenges that arise from a lack of evidence for DHPs is crucial.
  • This latest project from DiMe will address these obstacles to help streamline the path to broad adoption of evidence-based digital health technologies, build confidence with digital health purchasing organizations, and optimize health outcomes for the greatest number of patients – all while advancing innovation in the digital health landscape.
  • "Developers have been very successful at securing FDA acceptance and market access opportunities for their digital health products (DHPs).
  • This work builds on DiMe's successful U.S. Digital Health Regulatory Pathways for DHPs and Evidence DEFINED framework to advance the use of IEPs for developing DHPs.

Dime Announces Continued Partnership for the Dime McCarren 5K in 2024

Retrieved on: 
Wednesday, January 10, 2024

HAUPPAUGE, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM and DCOMP) (the “Company”) announced that it will return as the lead sponsor for the 5th consecutive year.

Key Points: 
  • HAUPPAUGE, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM and DCOMP) (the “Company”) announced that it will return as the lead sponsor for the 5th consecutive year.
  • The Dime McCarren 5K supports St Nick’s Alliance, which supports and manages affordable housing and educational programs for under privileged youth.

March of Dimes Global Crowdsourcing Effort Yields Pair of Predictive Models for Preterm Birth

Retrieved on: 
Thursday, December 21, 2023

The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.

Key Points: 
  • The 2023 March of Dimes Report Card shows that the U.S. preterm birth rate stands at 10.4%, a meager improvement from last year's historic high of 10.5%, the highest preterm birth rate in 10 years.
  • Key to the predictive models is their ability to estimate a woman's risk for two types of preterm birth—one before 37 weeks and the other before 32 weeks.
  • The models' predictive power was strong: One predicted preterm birth with a 69% accuracy, and the other predicted early preterm birth with an 86% accuracy.
  • On Big Data Analysis and Preterm Birth Risk Prediction" episode on MODCAST, March of Dimes' research podcast, here .

Summus Joins Digital Medicine Society, Boston Children's Hospital to Advance Healthcare Outcomes for Children, Close Disparity Gap

Retrieved on: 
Monday, December 18, 2023

NEW YORK, Dec. 18, 2023 /PRNewswire/ -- Summus, the leading virtual health company focused in specialty care, announced a new collaboration with the Digital Medicine Society (DiMe) and Boston Children's Hospital to create a comprehensive guide to improve digital health solutions for children. The Playbook: Pediatric Digital Medicine initiative will address the need for ongoing advancement and care optimization for children by empowering providers, payers, product developers, and biopharma to advance streamlined and scalable innovations in pediatrics.

Key Points: 
  • This multistakeholder effort aims to close the disparity gap in children's healthcare through access to technological advancements centered on children's unique needs, delivering ethical, effective, equitable and safe care.
  • Summus works closely with Boston Children's innovation team and physician facility to advance and scale specialist expertise to reach more patients globally.
  • Define the market opportunity for pediatric digital medicine products and establish best practices for product development and deployment.
  • The Playbook: Pediatric Digital Medicine will serve as an important resource, providing essential information for healthcare providers, hospitals, and industry partners."